Salomon Azoulay, M.D., serves as Chief Medical Officer at MBX Biosciences Inc., a clinical-stage biopharmaceutical company developing innovative therapies for endocrine and metabolic disorders. With over 25 years of experience in the biotechnology and pharmaceutical industries, Dr. Azoulay brings deep expertise in endocrinology, rare diseases, and metabolic conditions. He earned his medical degree from the University of Paris and completed residency and fellowship training in endocrinology and metabolism at prestigious institutions in France and the United States. Prior to joining MBX Biosciences, Dr. Azoulay held senior leadership roles at Ascendis Pharma, where he was Senior Vice President and Head of Development for Endocrinology and Metabolism, overseeing the advancement of multiple late-stage programs, including the successful development of TransCon PTH for hypoparathyroidism. Earlier in his career, he served as Executive Director at Pfizer, leading global clinical development for rare endocrine disorders, and held positions at Ipsen and Ferring Pharmaceuticals, contributing to the approval of several therapies for growth hormone deficiencies and other metabolic indications. His track record includes navigating complex regulatory pathways, managing Phase 1-3 trials, and forging key partnerships that have accelerated drug approvals. At MBX Biosciences, Dr. Azoulay leads the clinical development strategy for the company's pipeline, including MBX 2109, a novel therapy in Phase 2 for hypoparathyroidism, and other programs targeting hyperparathyroidism and obesity-related conditions. His strategic vision and operational excellence position MBX to deliver transformative treatments, leveraging his proven ability to translate scientific innovation into clinical success and patient impact.